Comparative Pharmacology
Head-to-head clinical analysis: KAITLIB FE versus NORINYL 1 80 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KAITLIB FE versus NORINYL 1 80 21 DAY.
KAITLIB FE vs NORINYL 1+80 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KAITLIB FE (levonorgestrel/ethinyl estradiol/ferrous fumarate) is a combined hormonal contraceptive. Levonorgestrel is a progestogen that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that stabilizes the endometrium and provides cycle control. The added ferrous fumarate is an iron supplement to treat iron deficiency anemia.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
One tablet (norethindrone 1 mg and ethinyl estradiol 0.02 mg, with ferrous fumarate 35 mg) orally once daily for 28 days (21 active pills, 7 placebo/iron pills).
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; clinically significant for once-daily dosing
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Renal: 40-60% as unchanged drug; biliary: 20-30% as metabolites; fecal: 10-20%
Renal (40-60% as metabolites), fecal (20-30%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive